The general hemodynamic effects induced by a continuous intravenous infusion of synthetic bradykinin were studied in ten patients submitted to simultaneous right- and left-heart catheterization. A significant drop in systemic arterial pressure and in total peripheral resistance was observed, coincident with an increase of the cardiac output, heart rate, and stroke volume. There was no consistent change of the pulmonary arterial and left atrial pressures, but the pulmonary vascular resistance decreased significantly.
Twenty-one patients with pulmonary hypertension secondary to rheumatic mitral valve disease were submitted to right and left heart catheterization and received a continuous intravenous infusion of synthetic bradykinin (average dose, 0.98 µg/kg/min).
The drug elicited an appreciable fall of the systemic vascular resistance simultaneously with a decrease of the mean systemic arterial pressure and an increase of the cardiac output in all cases. The rise in cardiac output derived mainly from an increase in heart rate, since the modifications of the stroke volume were generally of low magnitude.
In the pulmonary circulation, the increase in blood flow was coincident with a rise of the mean arterial and venous (left atrial) pressures in 19 and all patients, respectively. The pulmonary vascular resistance fell in 19 patients, but no appreciable modifications were noted in pulmonary blood volume.
The changes in the lesser circulation were interpreted as expressing secondary effects, either mechanical or reflex, consequent to the action of bradykinin on the systemic vessels and heart rather than a direct effect of the drug on the pulmonary vessels.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.